Overview
Decapeptide-12 is a synthetic peptide composed of ten amino acids, developed as a research compound with particular interest in its interactions with melanin synthesis pathways in skin biology. It is sometimes referred to by the trade name Lumixyl and carries the CAS number 137665-91-9. As a tyrosinase-inhibiting peptide, it belongs to a category of compounds studied for their potential to influence pigmentation-related cellular processes, making it a subject of interest in dermatological research. Published studies have investigated its comparative behavior alongside other well-known compounds involved in melanin regulation, as well as its delivery and absorption characteristics across skin tissue. Decapeptide-12 is intended for research purposes only and is not approved for human use or consumption.
Research & Bioactivity
Researchers have studied Decapeptide-12 primarily in the context of skin pigmentation biology, with a particular focus on its interactions with the melanin-producing enzyme tyrosinase. In vitro studies have examined its capacity to competitively inhibit both mushroom and human tyrosinase, positioning it as a subject of interest in research on melanogenesis regulation. Animal and human-subject studies have investigated its comparative safety profile relative to hydroquinone, a commonly referenced compound in pigmentation research, with some clinical trials reporting measurable reductions in melanin content following repeated topical application over several weeks. Double-blind, placebo-controlled clinical studies have explored its use in formulations targeting conditions such as melasma and post-inflammatory hyperpigmentation across diverse skin types, including populations of Hispanic, Asian, and other descents. Researchers have also investigated strategies to enhance the transcutaneous delivery of the peptide, given that its hydrophilic nature and relatively high molecular weight present challenges for skin permeation in experimental applications.
Published Research
Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.
Chen J, Bian J, Hantash BM, Albakr L, Hibbs DE, et al. — 2021
Hyperpigmentation is a common skin condition with serious psychosocial consequences. Decapeptide-12, a novel peptide, has been found to be safer than hydroquinone in reducing melanin content, with efficacy up to more than 50% upon 16 weeks of twice-daily treatment. However, the peptide suffers from limited transcutaneous penetration due to its hydrophilicity and high molecular weight. Therefore, decapeptide-12 was modified by adding a palmitate chain in an attempt to overcome this limitation. Molecular docking results showed that the two peptides exhibited similar biological activity towards tyrosinase. We also tested the effect of chemical penetration enhancers and microneedles to deliver the two peptides into and through skin, using an in vitro human skin permeation method. It was shown that the palm-peptide achieved the best skin retention owing to the increased lipophilicity. In addition, skin permeation of the palm-peptides was enhanced by the chemical skin penetration enhancers, namely, oleic acid and menthol. Skin permeation of the native peptide was enhanced by the microneedle patch but not the chemical skin penetration enhancers. Cutaneous absorption of the palm-peptides was estimated to have achieved its therapeutic concentration within skin. The combinatory approach of using molecular modification, chemical penetration enhancement, and microneedle patch proves to be useful to enhanceskin permeation of the peptides.
Efficacy of Trifecting Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study.
Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F — 2018
Melasma is a common, persistent disorder of hyperpigmented facial skin predominantly attributed to ultraviolet light exposure, hormonal influences, and genetic predisposition. This double-blind, placebo-controlled, randomized clinical trial was conducted to assess the efficacy and tolerance of a multimodality night cream when used over a course of 24 weeks followed by a four-week regression in female subjects with moderate to severe melasma, presence of solar lentigines, and periocular lines and wrinkles. Subjects were randomized into one of two groups: Cell 1 received Trifecting Night Cream (Envy Medical, Long Beach, California) 1.0 and Cell 2 did not. All subjects were supplied with a two-product regimen comprising a cleanser and sunscreen to use during the trial. Clinical grading, tolerability assessments, and Chroma Meter measurements (Konica Minolta, Tokyo, Japan) were performed at baseline and at Weeks 8, 16, 24, and 28 (regression). Standardized digital photographs were taken and self-assessment questionnaires were completed. Twenty-five subjects completed the 28-week study, with 14 subjects in Cell 1 and 11 subjects in Cell 2. Subjects in both groups showed improvements in facial conditions. Cell 1 outperformed Cell 2 in improving fine lines, solar lentigines, and melasma conditions. These improvements were sustained during regression period. Trifecting Night Cream 1.0, is effective for the treatment of moderate to severe melasma, solar lentigines, and periocular lines and wrinkles over 24 weeks of usage, with its benefits sustained for at least four weeks after treatment.
Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color.
Bhatia A, Hsu JTs, Hantash BM — 2014
Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.
Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, et al. — 2013
Melasma is a cutaneous disorder that primarily affects females of Hispanic and Asian descent. Previous studies have shown that use of a brightening system comprised of 0.01% decapeptide-12 cream, an antioxidant cleanser, a 20% buffered glycolic acid lotion, and a broad spectrum SPF 30 sunscreen yields good clearance of mild-to-moderate melasma in Caucasian and Asian volunteers. The present open-label, prospective, and multicenter study sought to determine the tolerability and efficacy of the above-mentioned brightening system on mild-to-moderate melasma in 33 Hispanic females over 16 weeks. Clinical measures included self-assessment of tolerability, clinical grading, determination of Melasma Area and Severity Index (MASI) scores, and standardized clinical photography. Results showed that the system was well tolerated with no adverse events reported. Mean decreases of 36%, 46%, 54%, and 60% in MASI scores were observed at weeks 4, 8, 12, and 16, respectively, which were further corroborated by standardized photography showing visible reduction in the appearance of melasma. Results suggest that the brightening system consisting of 0.01% decapeptide-12 cream, an antioxidant cleanser, 20% buffered glycolic acid lotion, and broad spectrum SPF 30 sunscreen is safe and efficacious for the treatment of mild-to-moderate melasma in Hispanic females.
Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.
Hantash BM, Jimenez F — 2012
BACKGROUND: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. OBJECTIVE: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma. RESULTS: All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks. CONCLUSIONS: Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.